Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 7Carcinoma, Neuroendocrine 6Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Lung Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Non-Small-Cell Lung 2Somatostatinoma 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Large Cell 1

Interventions

Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extrapulmonary Neuroendocrine Cancer × Carboplatin × Endocrine × Clear all
NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡